publication date: Dec. 17, 2018

Conversation with The Cancer Letter Amy Abernethy to join FDA as principal deputy commissioner

Amy Abernethy

Chief medical officer, chief scientific officer, senior vice president of oncology, Flatiron Health


Amy Abernethy, a thought leader in the field of evidence generation and the development of real-world evidence, was named principal deputy commissioner at FDA.

Abernethy, who is now the chief medical officer, chief scientific officer and senior vice president of oncology at Flatiron Health, is expected to start at the agency in February 2019 after leaving Flatiron. She will replace Rachel Sherman, who oversees clinical, scientific, regulatory, and operational medical programs and initiatives across the agency. Sherman is retiring after 30 years of service at FDA.

“I am very excited,” Abernethy said to The Cancer Letter. “It’s a bit daunting and also a big step and change in what I do everyday in my career, but overall, it feels like the right thing to do both from the standpoint of how to continue to work on the things that I’ve been working on for the last 20 years, as well as from a career standpoint. And also, I’ve always wanted to be in public service.”

Prior to joining Flatiron, Abernethy was professor of medicine at Duke University School of Medicine and ran the … Continue reading Amy Abernethy to join FDA as principal deputy commissioner

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.